Lantern Pharma Launches AI Drug Development Hub in India to Scale Cancer Research | NewsOut

Biotech and AI investors: Lantern Pharma has announced the launch of a new AI center in Bengaluru, India, designed to scale its artificial intelligence capabilities for drug development and global biopharma partnerships.

Reporting from the New York Stock Exchange, Jane King explains that the hub will support enterprise-scale deployment of Lantern’s AI platform, with Phase One focused on biomarker discovery and clinical trial optimization in cancer, followed by expansion into inflammation, immunology, and neurodegenerative diseases such as Alzheimer’s.

#LanternPharma
#AIinBiotech
#DrugDevelopment
#CancerResearch
#PrecisionOncology
#ClinicalTrials
#BiotechInnovation
#ArtificialIntelligence
#Bengaluru
#IndiaTech
#JaneKing
#NewsOut
#NYSE
#PharmaAI